Oragenics gains on positive pre-clinical COVID-19 vaccine study results

Oragenics

01/12/2021 14:12

** Drug developer's  OGEN.A  shares rise 9% premarket to 62
cents, set for its highest in nearly three weeks, after co
announces positive hamster study results for its SARS-CoV-2
vaccine candidate
    ** Both intranasal and intramuscular formulations generated
robust immune responses and reduced viral loads to undetectable
levels in the nasal passages and lungs five days following a
viral challenge, co says  urn:newsml:reuters.com:*:nBw7DnCTMa
    ** OGEN adds that findings from the study will be part of
its Investigational New Drug filing to the U.S. FDA, expected in
Q2 of 2022, which could advance the study into clinical studies
    ** Shares up 28% YTD
    

 (Reporting by Anisha Sircar in Bengaluru)
 ((Anisha.Sircar@thomsonreuters.com;))